nach oben

Medical Oncology

Erschienen in:

01.02.2015 | Original Paper

Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies

verfasst von: Wenjie Xia, Youtao Xu, Qixing Mao, Gaochao Dong, Run Shi, Jie Wang, YanYan Zheng, Lin Xu, Feng Jiang

Erschienen in: Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The receptor for advanced glycation end products (RAGE), a member of immunoglobulin superfamily, has been proved to stimulate survival, growth, and metastatic spread of cancers cells. Evidence suggested that the 82G/S, −374T/A, and −429T/C polymorphisms in RAGE promoter region might affect the risk of cancer; however, data from epidemiological studies showed conflicting results that remain to be further clarified. This meta-analysis was performed to derive a more precise estimation of 82G/S, −374T/A, and −429T/C polymorphisms and risk of cancer. A comprehensive electronic search was conducted for articles published up until December 2, 2014, in Medline (PubMed), Embase, the Cochrane Library and Google Scholar. A total of 12 case–control articles were included in this meta-analysis, providing 3,374 cases and 3,757 controls for 82G/S, 2,936 cases and 3,338 controls for −374T/A, and 2,882 cases and 3,279 controls for −429T/C specifically. The pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated to evaluate the associations with risk of cancer. Overall, we observed significantly increased risk of cancer in relation to 82G/S (A vs. G: OR 1.321, 95 % CI 1.164–1.499, P _het 0.028; AA vs. GG: OR 1.823, 95 % CI 1.541–2.157, P _het < 0.001; AG vs. GG: OR 1.399, 95 % CI 1.120–1.746, P _het 0.002; GA+AA vs. GG: OR 1.470, 95 % CI 1.187–1.821, P _het 0.002; AA vs. GG+AG: OR 1.416, 95 % CI 1.158–1.732, P _het 0.107) and reduced risk of cancer in relation to −374T/A (AA vs. TT: OR 0.818, 95 % CI 0.686–0.976, P _het 0.025; A vs. T: OR 0.908, 95 % CI 0.840–0.981, P _het 0.014). In subgroup analysis for 82G/S, a significantly elevated cancer risk was indicated in the population of Asian and patients with lung cancer, and for −374T/A, reduced risk was indicated in population of Caucasian and patients with lung cancer and breast cancer. But no significant association was observed between −429T/C and risk of cancer. Thus, this meta-analysis revealed that 82G/S polymorphism is associated with a significantly increased risk of cancer, while −374T/A polymorphism is associated with a reduced risk of cancers.

Nur mit Berechtigung zugänglich

Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998–5004.PubMed

Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4(5):285–93. doi:10.1038/ncpendmet0786.PubMedCrossRef

Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007;7(8):743–51.PubMedCrossRef

Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198(10):1507–15. doi:10.1084/jem.20030800.PubMedCentralPubMedCrossRef

Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Investig. 2001;108(7):949–55. doi:10.1172/JCI14002.PubMedCentralPubMedCrossRef

Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83(11):876–86. doi:10.1007/s00109-005-0688-7.PubMedCrossRef

Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl med. 2009;7:38. doi:10.1186/1479-5876-7-38.PubMedCentralPubMedCrossRef

Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13(10):2836–48. doi:10.1158/1078-0432.CCR-06-1953.PubMedCrossRef

Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate. 2005;64(1):92–100. doi:10.1002/pros.20219.PubMedCrossRef

10.

Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196(2):163–70. doi:10.1002/path.1031.PubMedCrossRef

11.

Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2010;136(5):677–84. doi:10.1007/s00432-009-0706-1.PubMedCrossRef

12.

Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol. 2009;578:3–22. doi:10.1007/978-1-60327-411-1_1.PubMedCrossRef

13.

Dabritz J, Friedrichs F, Weinhage T, Hampe J, Kucharzik T, Lugering A, et al. The functional −374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G823–32. doi:10.1152/ajpgi.00115.2010.PubMedCrossRef

14.

Picheth G, Heidemann M, Pedrosa FO, Chautard-Freire-Maia EA, Costantini CO, da Rocha Martinez TL, et al. The -429 T > C polymorphism of the receptor for advanced glycation end products (RAGE) is associated with type 1 diabetes in a Brazilian population. Clin Chim Acta. 2007;383(1–2):163–4. doi:10.1016/j.cca.2007.03.026.PubMedCrossRef

15.

Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metab Clin Exp. 2007;56(2):199–205. doi:10.1016/j.metabol.2006.09.013.PubMedCrossRef

16.

Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes. 1998;47(7):1155–7.PubMedCrossRef

17.

Pan H, Niu W, He L, Wang B, Cao J, Zhao F, et al. Contributory role of five common polymorphisms of RAGE and APE1 genes in lung cancer among Han Chinese. PLoS One. 2013;8(7):e69018. doi:10.1371/journal.pone.0069018.PubMedCentralPubMedCrossRef

18.

Schenk S, Schraml P, Bendik I, Ludwig CU. A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer. 2001;32(1):7–12.PubMedCrossRef

19.

Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, et al. RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One. 2012;7(10):e43734. doi:10.1371/journal.pone.0043734.PubMedCentralPubMedCrossRef

20.

Krechler T, Jachymova M, Mestek O, Zak A, Zima T, Kalousova M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem. 2010;43(10–11):882–6. doi:10.1016/j.clinbiochem.2010.04.004.PubMedCrossRef

21.

Qian F, Sun BL, Zhang WY, Ke J, Zhu J. Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer. Tumour Biol. 2014;35(4):3171–5. doi:10.1007/s13277-013-1414-7.PubMedCrossRef

22.

Xu Q, Xue F, Yuan B, Zhang L, Li J, He Z. The interaction between RAGE gene polymorphisms and HPV infection in determining the susceptibility of cervical cancer in a Chinese population. Cancer Biomark. 2012;11(4):147–53. doi:10.3233/CBM-2012-00277.PubMed

23.

Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B. Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem. 2013;31(4–5):525–31. doi:10.1159/000350073.PubMedCrossRef

24.

Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R, et al. Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res. 2008;14(11):3627–32. doi:10.1158/1078-0432.CCR-07-4808.PubMedCrossRef

25.

Hashemi M, Moazeni-Roodi A, Arbabi F, Fazaeli A, Nasab EE, Taheri M, et al. Genotyping of -374A/T, -429A/G, and 63 bp Ins/del polymorphisms of RAGE by rapid one-step hexaprimer amplification refractory mutation system polymerase chain reaction in breast cancer patients. Nucleosides Nucleotides Nucleic Acids. 2012;31(5):401–10. doi:10.1080/15257770.2012.665545.PubMedCrossRef

26.

Pan H, He L, Wang B, Niu W. The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese. Sci Rep. 2014;4:4355. doi:10.1038/srep04355.PubMed

27.

Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE)–soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007;25(8):720–5. doi:10.1080/07357900701560521.PubMedCrossRef

28.

Chocholaty M, Jachymova M, Schmidt M, Havlova K, Krepelova A, Zima T, et al. Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer. Tumour Biol. 2014;. doi:10.1007/s13277-014-2821-0.PubMed

29.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef

30.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRef

31.

Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Investig. 1996;97(1):238–43. doi:10.1172/JCI118397.PubMedCentralPubMedCrossRef

32.

Meloche J, Paulin R, Courboulin A, Lambert C, Barrier M, Bonnet P, et al. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol. 2011;31(9):2114–24. doi:10.1161/ATVBAHA.111.230573.PubMedCentralPubMedCrossRef

33.

Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 2011;9(2):133–48. doi:10.1158/1541-7786.MCR-10-0394.PubMedCentralPubMedCrossRef

34.

Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Archiv. 2005;446(4):411–5. doi:10.1007/s00428-005-1210-x.PubMedCrossRef

35.

Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis. 2005;26(2):293–301. doi:10.1093/carcin/bgh333.PubMedCrossRef

36.

Hofmann HS, Hansen G, Burdach S, Bartling B, Silber RE, Simm A. Discrimination of human lung neoplasm from normal lung by two target genes. Am J Respir Crit Care Med. 2004;170(5):516–9. doi:10.1164/rccm.200401-127OC.PubMedCrossRef

37.

Schraml P, Bendik I, Ludwig CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res. 1997;57(17):3669–71.PubMed

38.

Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405(6784):354–60. doi:10.1038/35012626.PubMedCrossRef

39.

Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004;279(7):5059–65. doi:10.1074/jbc.M310124200.PubMedCrossRef

40.

Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 2002;62(16):4805–11.PubMed

41.

Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 2005;11(15):5356–64. doi:10.1158/1078-0432.CCR-05-0092.PubMedCrossRef

Titel: Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies
verfasst von: Wenjie Xia
Youtao Xu
Qixing Mao
Gaochao Dong
Run Shi
Jie Wang
YanYan Zheng
Lin Xu
Feng Jiang
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0442-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial

Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR–ABL1 fusion

SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway

Survivorship in untreated breast cancer patients

Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma

Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie